Secretaría de Gobernación
CONACYT
INGER
  2. Repositorio Institucional
  3. 1. Artículos
Mi INGER Alertas Editar perfil
Por favor, use este identificador para citar o enlazar este ítem: http://repositorio.inger.gob.mx/jspui/handle/20.500.12100/17274
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.rights.licensehttp://creativecommons.org/licenses/by/4.0es_MX
dc.creatorNORMA EDITH LOPEZ DIAZ GUERREROes_MX
dc.creatorGLORIA ERANDI PEREZ FIGUEROAes_MX
dc.creatorCintia Mayel Martínez Garduñoes_MX
dc.creatorADRIANA ALARCON AGUILARes_MX
dc.creatorARMANDO LUNA LOPEZes_MX
dc.creatorMARIA CONCEPCION GUTIERREZ RUIZes_MX
dc.creatorMINA KONIGSBERG FAINSTEINes_MX
dc.date2012-
dc.date.accessioned2021-10-26T22:31:01Z-
dc.date.available2021-10-26T22:31:01Z-
dc.identifier.urihttp://repositorio.inger.gob.mx/jspui/handle/20.500.12100/17274-
dc.descriptionWe have analysed telomerase activity to determine whether it can be modified when BCL-2 is endogenously overexpressed in response to a mild oxidative stress treatment as part of a survival mechanism, in contrast with an exogenous bcl-2 overexpression due to a retroviral infection. Endogenous bcl-2 overexpression was induced after a low oxidative insult of H2O2 in mice primary lung fibroblasts and L929 cell, whereas bcl-2 exogenous overexpression was performed using a retroviral infection in L929 cells. Telomerase activity was quantified in Bcl-2 overexpressing cells by the TRAP assay. When the cells were treated with different H2O2 concentrations, only those exposed to 50 μM showed increased telomerase activity. This correlates with BCL-2 expression as part of the endogenous response to mild oxidative stress. Oxidative stress generated during the toxic mechanism of chemotherapeutic drugs might induce BCL-2 increment, enhancing telomerase activity and reactivating the oncogenic process. Clinical trials should take into consideration the possibility of telomerase activation following increased BCL-2 expression when treating patients with ROS (reactive oxygen species) generation by anti-cancer drugs.es_MX
dc.formatAdobe PDFes_MX
dc.languageenges_MX
dc.publisherInternational Federation for Cell Biology International & Wileyes_MX
dc.relationhttps://onlinelibrary.wiley.com/doi/abs/10.1042/CBI20110308?__cf_chl_jschl_tk__=pmd_k1TShev6lGBob2kLKbW3Z8LalbBfIV7Y7iZY0fG8hAE-1635287187-0-gqNtZGzNAjujcnBszQsles_MX
dc.relation.requiresSies_MX
dc.rightsAcceso Abiertoes_MX
dc.sourceCell Biology International (1095-8355) Vol. 36 (2012)es_MX
dc.subjectBIOLOGÍA Y QUÍMICAes_MX
dc.subjectQuímicaes_MX
dc.subjectBioqímicaes_MX
dc.subjectEnzimologíaes_MX
dc.subjectMetabolismoes_MX
dc.subjectEstres oxidativoes_MX
dc.subjectBCL-2es_MX
dc.subjectDrogras quimioterapéuticases_MX
dc.subjectOxidative stresses_MX
dc.subjectChemistryes_MX
dc.subjectBiochemistryes_MX
dc.subjectChemotherapeutic drugses_MX
dc.titleTelomerase activity in response to mild oxidative stresses_MX
dc.typeArtículoes_MX
dc.audienceResearcherses_MX
dc.creator.idLODN680314MDFPZR02es_MX
dc.creator.idPEFG850430MDFRGL09es_MX
dc.creator.idCA1219302es_MX
dc.creator.idAAAA791115MHGLGD08es_MX
dc.creator.idLULA690630HDFNPR02es_MX
dc.creator.idGURC540106MDFTZN00es_MX
dc.creator.idKOFM650625MDFNNN02es_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercaes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
Aparece en las colecciones: 1. Artículos

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Cell Biology International (1095-8355) Vol. 36 (2012).pdf302.23 kBAdobe PDFVisualizar/Abrir
Mostrar el registro sencillo del ítem